Critical Review: Demand Brands (OTCMKTS:DMAN) and Incannex Healthcare (NASDAQ:IXHL)

Demand Brands (OTCMKTS:DMAN) and Incannex Healthcare (NASDAQ:IXHL) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings & Valuation

This table compares Demand Brands and Incannex Healthcare”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Demand Brands	N/A	N/A	N/A	($0.59)	-0.00
Incannex Healthcare	N/A	N/A	-$46.88 million	($1.55)	-2.09

Incannex Healthcare is trading at a lower price-to-earnings ratio than Demand Brands, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Demand Brands and Incannex Healthcare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Demand Brands	N/A	N/A	N/A
Incannex Healthcare	N/A	-81.01%	-76.11%

Insider & Institutional Ownership

98.1% of Demand Brands shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 2.2% of Demand Brands shares are held by company insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Demand Brands and Incannex Healthcare, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Demand Brands	0	0	0	0	0.00
Incannex Healthcare	1	0	1	0	2.00

Incannex Healthcare has a consensus target price of $18.00, suggesting a potential upside of 455.56%. Given Incannex Healthcare’s stronger consensus rating and higher probable upside, analysts plainly believe Incannex Healthcare is more favorable than Demand Brands.

Summary

Demand Brands beats Incannex Healthcare on 6 of the 9 factors compared between the two stocks.

About Demand Brands

Demand Brands, Inc. focuses on developing electroseismic applications and drone programs technologies for the energy industry. The company is based in Santa Monica, California.

About Incannex Healthcare

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.